海昇药业：股东王小青拟减持不超180万股，占总股本1.8%

Core Viewpoint - Haisheng Pharmaceutical announced that its shareholder Wang Xiaoqing, holding 24.5046% of the shares, plans to reduce his stake by up to 1,800,000 shares, representing 1.8% of the total share capital, within three months after 15 trading days from the announcement date, due to personal financial arrangements [1] Group 1 - Wang Xiaoqing's planned reduction of shares is set to occur through centralized bidding or block trading [1] - The reduction price will be determined based on market trading prices [1] - The shares to be reduced were acquired before the listing on the Beijing Stock Exchange, including those from rights distribution and capital increase [1]